BWA
CRNX icon

Basecamp Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Basecamp Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76K Hold
47
– – ﹤0.01% 1401
2026
Q1 		$1.71K Sell
47
-116
-71% -$5.18K ﹤0.01% 1439
2025
Q4 		$7.59K Buy
+163
New +$7.26K ﹤0.01% 1049

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's CRNX Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 47 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

Basecamp Wealth Advisors first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.59K in Q4 2025. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Basecamp Wealth Advisors held 47 shares of Crinetics Pharmaceuticals worth $1.76K as of Q2 2026.
  • Basecamp Wealth Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1401 holding.
  • Basecamp Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Crinetics Pharmaceuticals position peaked at $7.59K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.